Abstract
Enforced expression of microRNA-155 (miR-155) in myeloid cells has been shown to have both oncogenic or tumour-suppressor functions in acute myeloid leukaemia (AML). We sought to resolve these contrasting effects of miR-155 overexpression using murine models of AML and human paediatric AML data sets. We show that the highest miR-155 expression levels inhibited proliferation in murine AML models. Over time, enforced miR-155 expression in AML in vitro and in vivo, however, favours selection of intermediate miR-155 expression levels that results in increased tumour burden in mice, without accelerating the onset of disease. Strikingly, we show that intermediate and high miR-155 expression also regulate very different subsets of miR-155 targets and have contrasting downstream effects on the transcriptional environments of AML cells, including genes involved in haematopoiesis and leukaemia. Furthermore, we show that elevated miR-155 expression detected in paediatric AML correlates with intermediate and not high miR-155 expression identified in our experimental models. These findings collectively describe a novel dose-dependent role for miR-155 in the regulation of AML, which may have important therapeutic implications.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Estey E, Döhner H . Acute myeloid leukaemia. Lancet 2006; 368: 1894–1907.
Bartel DP . MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281–297.
Lujambio A, Lowe SW . The microcosmos of cancer. Nature 2012; 482: 347–355.
Tam W . Identification and characterization of human BIC, a gene on chromosome 21 that encodes a noncoding RNA. Gene 2001; 274: 157–167.
Eis PS, Tam W, Sun L, Chadburn A, Li Z, Gomez MF et al. Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad Sci USA 2005; 102: 3627–3632.
Kluiver J, Poppema S, de Jong D, Blokzijl T, Harms G, Jacobs S et al. BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas. J Pathol 2005; 207: 243–249.
Costinean S, Zanesi N, Pekarsky Y, Tili E, Volinia S, Heerema N et al. Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice. Proc Natl Acad Sci USA 2006; 103: 7024–7029.
Costinean S, Sandhu SK, Pedersen IM, Tili E, Trotta R, Perrotti D et al. Src homology 2 domain-containing inositol-5-phosphatase and CCAAT enhancer-binding protein beta are targeted by miR-155 in B cells of Emicro-MiR-155 transgenic mice. Blood 2009; 114: 1374–1382.
Danen-van Oorschot AA, Kuipers JE, Arentsen-Peters S, Schotte D, de Haas V, Trka J et al. Differentially expressed miRNAs in cytogenetic and molecular subtypes of pediatric acute myeloid leukemia. Pediatr Blood Cancer 2012; 58: 715–721.
Faraoni I, Laterza S, Ardiri D, Ciardi C, Fazi F, Lo-Coco F . MiR-424 and miR-155 deregulated expression in cytogenetically normal acute myeloid leukaemia: correlation with NPM1 and FLT3 mutation status. J Hematol Oncol 2012; 5: 26.
Garzon R, Garofalo M, Martelli MP, Briesewitz R, Wang L, Fernandez-Cymering C et al. Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. Proc Natl Acad Sci USA 2008; 105: 3945–3950.
Garzon R, Volinia S, Liu C-G, Fernandez-Cymering C, Palumbo T, Pichiorri F et al. MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood 2008; 111: 3183–3189.
Gerloff D, Grundler R, Wurm AA, Brauer-Hartmann D, Katzerke C, Hartmann JU et al. NF-kappaB/STAT5/miR-155 network targets PU.1 in FLT3-ITD-driven acute myeloid leukemia. Leukemia 2015; 29: 535–547.
O'Connell RM, Rao DS, Chaudhuri AA, Boldin MP, Taganov KD, Nicoll J et al. Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder. J Exp Med 2008; 205: 585–594.
Georgantas RW III, Hildreth R, Morisot S, Alder J, Liu CG, Heimfeld S et al. CD34+ hematopoietic stem-progenitor cell microRNA expression and function: a circuit diagram of differentiation control. Proc Natl Acad Sci USA 2007; 104: 2750–2755.
Forrest AR, Kanamori-Katayama M, Tomaru Y, Lassmann T, Ninomiya N, Takahashi Y et al. Induction of microRNAs, mir-155, mir-222, mir-424 and mir-503, promotes monocytic differentiation through combinatorial regulation. Leukemia 2010; 24: 460–466.
Palma CA, Sheikha DA, Lim TK, Bryant A, Vu TT, Jayaswal V et al. MicroRNA-155 as an inducer of apoptosis and cell differentiation in acute myeloid leukemia. Mol Cancer 2014; 13: 1–8.
Salmanidis M, Brumatti G, Narayan N, Green BD, van den Bergen JA, Sandow JJ et al. Hoxb8 regulates expression of microRNAs to control cell death and differentiation. Cell Death Differ 2013; 20: 1370–1380.
Wu D, Smyth GK . Camera: a competitive gene set test accounting for inter-gene correlation. Nucleic Acids Res 2012; 40: e133.
Loeb GB, Khan AA, Canner D, Hiatt JB, Shendure J, Darnell RB et al. Transcriptome-wide miR-155 binding map reveals widespread noncanonical microRNA targeting. Mol Cell 2012; 48: 760–770.
Lewis BP, Burge CB, Bartel DP . Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005; 120: 15–20.
Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huerta-Cepas J et al. STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res 2015; 43: D447–D452.
Hart SM, Foroni L . Core binding factor genes and human leukemia. Haematologica 2002; 87: 1307–1323.
Huang Y, Sitwala K, Bronstein J, Sanders D, Dandekar M, Collins C et al. Identification and characterization of HoxA9 binding sites in hematopoietic cells. Blood 2012; 119: 388–398.
Hu YL, Fong S, Largman C, Shen WF . HOXA9 regulates miR-155 in hematopoietic cells. Nucleic Acids Res 2010; 38: 5472–5478.
Vigorito E, Perks KL, Abreu-Goodger C, Bunting S, Xiang Z, Kohlhaas S et al. microRNA-155 regulates the generation of immunoglobulin class-switched plasma cells. Immunity 2007; 27: 847–859.
Lu D, Nakagawa R, Lazzaro S, Staudacher P, Abreu-Goodger C, Henley T et al. The miR-155-PU.1 axis acts on Pax5 to enable efficient terminal B cell differentiation. J Exp Med 2014; 211: 2183–2198.
Vargova K, Curik N, Burda P, Basova P, Kulvait V, Pospisil V et al. MYB transcriptionally regulates the miR-155 host gene in chronic lymphocytic leukemia. Blood 2011; 117: 3816–3825.
Ghani S, Riemke P, Schonheit J, Lenze D, Stumm J, Hoogenkamp M et al. Macrophage development from HSCs requires PU.1-coordinated microRNA expression. Blood 2011; 118: 2275–2284.
Marcucci G, Maharry KS, Metzeler KH, Volinia S, Wu YZ, Mrozek K et al. Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients. J Clin Oncol 2013; 31: 2086–2093.
Morenos L, Chatterton Z, Ng JL, Halemba MS, Parkinson-Bates M, Mechinaud F et al. Hypermethylation and down-regulation of DLEU2 in paediatric acute myeloid leukaemia independent of embedded tumour suppressor miR-15a/16-1. Mol Cancer 2014; 13: 123.
Bibikova M, Barnes BT, Chan T, Ho V, Klotzle B, Le JM et al. High density DNA methylation array with single CpG site resolution. Genomics 2011; 98: 288–295.
Tili E, Croce CM, Michaille JJ . miR-155: on the crosstalk between inflammation and cancer. Int Rev Immunol 2009; 28: 264–284.
O'Connell RM, Taganov KD, Boldin MP, Cheng G, Baltimore D . MicroRNA-155 is induced during the macrophage inflammatory response. Proc Natl Acad Sci USA 2007; 104: 1604–1609.
Rodriguez A, Vigorito E, Clare S, Warren MV, Couttet P, Soond DR et al. Requirement of bic/microRNA-155 for normal immune function. Science 2007; 316: 608–611.
Dorsett Y, McBride KM, Jankovic M, Gazumyan A, Thai TH, Robbiani DF et al. MicroRNA-155 suppresses activation-induced cytidine deaminase-mediated Myc-Igh translocation. Immunity 2008; 28: 630–638.
Thai TH, Calado DP, Casola S, Ansel KM, Xiao C, Xue Y et al. Regulation of the germinal centre response by microRNA-155. Science 2007; 316: 604–608.
Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006; 9: 189–198.
Kong W, He L, Coppola M, Guo J, Esposito NN, Coppola D et al. MicroRNA-155 regulates cell survival, growth, and chemosensitivity by targeting FOXO3a in breast cancer. J Biol Chem 2010; 285: 17869–17879.
Hirai H, Zhang P, Dayaram T, Hetherington CJ, Mizuno S, Imanishi J et al. C/EBPbeta is required for 'emergency' granulopoiesis. Nat Immunol 2006; 7: 732–739.
Cook WD, McCaw BJ, Herring C, John DL, Foote SJ, Nutt SL et al. PU.1 is a suppressor of myeloid leukemia, inactivated in mice by gene deletion and mutations of its DNA binding domain. Blood 2004; 104: 3437–3444.
Scott EW, Simon MC, Anastasi J, Singh H . Requirement of transcription factor PU.1 in the development of multiple hematopoietic lineages. Science 1994; 265: 1573–1577.
Hegde SP, Zhao JF, Ashmun RA, Shapiro LH . c-Maf induces monocytic differentiation and apoptosis in bipotent myeloid progenitors. Blood 1999; 94: 1578–1589.
Rego EM, Wang Z-G, Peruzzi D, He L-Z, Cordon-Cardo C, Pandolfi PP . Role of promyelocytic leukemia (PML) protein in tumour suppression. J Exp Med 2001; 193: 521–529.
Kakizuka A, Miller WHJ, Umesono K, Warrell RPJ, Frankel SR, VVVS Murty et al. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RARα with a novel putative transcription factor, PML. Cell 1991; 66: 663–674.
Khalife J, Radomska HS, Santhanam R, Huang X, Neviani P, Saultz J et al. Pharmacological targeting of miR-155 via the NEDD8-activating enzyme inhibitor MLN4924 (Pevonedistat) in FLT3-ITD acute myeloid leukemia. Leukemia 2015; 29: 1981–1992.
Daniels DL, Weis WI . Beta-catenin directly displaces Groucho/TLE repressors from Tcf/Lef in Wnt-mediated transcription activation. Nat Struct Mol Biol 2005; 12: 364–371.
Simon M, Grandage VL, Linch DC, Khwaja A . Constitutive activation of the Wnt/beta-catenin signalling pathway in acute myeloid leukaemia. Oncogene 2005; 24: 2410–2420.
Wang Y, Krivtsov AV, Sinha AU, North TE, Goessling W, Feng Z et al. The Wnt/b-catenin pathway is required for the development of leukemia stem cells in AML. Science 2010; 327: 1650–1653.
Hess JL, Bittner CB, Zeisig DT, Bach C, Fuchs U, Borkhardt A et al. c-Myb is an essential downstream target for homeobox-mediated transformation of hematopoietic cells. Blood 2006; 108: 297–304.
Zuber J, Rappaport AR, Luo W, Wang E, Chen C, Vaseva AV et al. An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance. Genes Dev 2011; 25: 1628–1640.
Friedman RC, Farh KK, Burge CB, Bartel DP . Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009; 19: 92–105.
Garcia DM, Baek D, Shin C, Bell GW, Grimson A, Bartel DP . Weak seed-pairing stability and high target-site abundance decrease the proficiency of lsy-6 and other microRNAs. Nat Struct Mol Biol 2011; 18: 1139–1146.
Goemans BF, Zwaan CM, Miller M, Zimmermann M, Harlow A, Meshinchi S et al. Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia. Leukemia 2005; 19: 1536–1542.
Beghini A, RIpamonti CB, Cairoli R, Cazzaniga G, Colapietro P, Elice F et al. KIT activating mutations: incidence in adult and pediatric acute myeloid leukemia, and identification of an internal tandem duplication. Hematologica 2004; 89: 920–925.
Shu J, Xia Z, Li L, Liang ET, Slipek N, Shen D et al. Dose-dependent differential mRNA target selection and regulation by let-7a-7 f and miR-17-92 cluster microRNAs. RNA Biol 2012; 9: 1275–1287.
Mukherji S, Ebert MS, Zheng GX, Tsang JS, Sharp PA, van Oudenaarden A . MicroRNAs can generate thresholds in target gene expression. Nat Genet 2011; 43: 854–859.
Faber J, Krivtsov AV, Stubbs MC, Wright R, Davis TN, van den Heuvel-Eibrink M et al. HOXA9 is required for survival in human MLL-rearranged acute leukemias. Blood 2009; 113: 2375–2385.
Acknowledgements
We thank the staff at WEHI Bioservices (Crystal Stivala, Nicole Lynch, Julie Merryfull and Jessica Mansheim) for assistance with animal work; the staff at WEHI Flow Facility for assistance with FACS sorting; Dr Francoise Mechinaud (Head of Oncology, Royal Children's Hospital), Dr Ngaire Elwood (Cord blood bank, MCRI), Dr Nick Wong (MCRI), Minhee Halemba (MCRI) and Jane Ng (MCRI) for procurement and preparation of paediatric samples. Grants from the Leukaemia Foundation (Australia), the National Health and Medical Research (NHMRC) Project grant, the Victorian Cancer Agency, My Room and the Children’s Cancer Centre Foundation supported paediatric AML work. We thank the Children’s Cancer Centre Tissue Bank (MCRI, The Royal Children’s Hospital) for supplying tumour samples and coded data, which is funded through generous support by CIKA (Cancer In Kids @ RCH), Leukaemia Auxiliary at RCH, MCRI and the Royal Children’s Hospital. We also thank Aedan Roberts and Aysen Yuksel for sample preparation at the Tumour Bank at the Children's Hospital at Westmead, which is generously supported by The Kids Cancer Project. We are greatful to Dr Johannes Zuber (The Research Institute of Molecular Pathology, Austria) for MYB and KIT shRNAs and Drs Mark McKenzie (WEHI), Luisa Cimmino (NYU School of Medicine, New York) and Ross Dickins (Monash University) for PU.1 shRNAs. We thank Andrew Bert (SA Pathology, Australia) for valuable technical expertise. Paul G Ekert is supported by the Children’s Cancer Foundation and the Steven Walter Children’s Cancer Foundation. Nisha Narayan was supported by the Australian Postgraduate Award PhD scholarship (University of Melbourne).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on the Leukemia website
Supplementary information
Rights and permissions
About this article
Cite this article
Narayan, N., Morenos, L., Phipson, B. et al. Functionally distinct roles for different miR-155 expression levels through contrasting effects on gene expression, in acute myeloid leukaemia. Leukemia 31, 808–820 (2017). https://doi.org/10.1038/leu.2016.279
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2016.279
This article is cited by
-
Outside the limit: questioning the distance restrictions for cooperative miRNA binding sites
Cellular & Molecular Biology Letters (2023)
-
Pathogenic Mechanisms in Acute Myeloid Leukemia
Current Treatment Options in Oncology (2022)
-
MiRNAs in cancer therapy: focusing on their bi-directional roles
ExRNA (2019)
-
Alleviating the progression of acute myeloid leukemia (AML) by sulforaphane through controlling miR-155 levels
Molecular Biology Reports (2018)
-
miR-155 in cancer drug resistance and as target for miRNA-based therapeutics
Cancer and Metastasis Reviews (2018)